Interim Review of Safety, Tolerability, and Efficacy From a First-In-Human Phase 1/2a Clinical Study of ICM-203, an Intra-Articular, AAV Gene Therapy for Osteoarthritis

被引：0
|
作者：
Heald, Alison E. [1 ,2 ]
Solomon, Bogdan [3 ]
Page, Richard [4 ,5 ]
Ahn, Yoenhee [1 ]
Yum, Young Na [1 ]
Myung, Jayhyuk [1 ]
Collins, Jamie E. [6 ]
Guermazi, Ali [7 ]
Kim, Dae-Won [1 ,8 ]
机构：
[1] ICM Co LTD, Seoul, South Korea
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[4] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia
[5] Deakin Univ, Geelong, Vic, Australia
[6] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[7] Boston Univ, Sch Med, Boston, MA 02118 USA
[8] Yonsei Univ, Seoul, South Korea
来源：
MOLECULAR THERAPY | 2024年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
146
引用
收藏
页码：80 / 80
页数：1
相关论文
共 42 条
  • [1] INTERIM DATA FROM THE FIRST-IN-HUMAN PHASE 1/2A TRIAL OF ICM-203, AN INTRA-ARTICULAR, AAV GENE THERAPY FOR OSTEOARTHRITIS - SAFETY, TOLERABILITY, AND PRELIMINARY EVALUATION OF CLINICAL ACTIVITY IN LOW DOSE COHORT
    Heald, Alison E.
    Solomon, Lucien B.
    Page, Richard
    Ahn, Yoenhee
    Yum, Young Na
    Myung, Jayhyuk
    Collins, Jamie E.
    Guermazi, Ali
    Kim, Dae-Won
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S589 - S589
  • [2] Interim Data from the First-in-Human Phase 1 Trial of FX201, an Intra-Articular, Helper-Dependent Adenoviral Gene Therapy for Osteoarthritis - Safety, Tolerability, Biodistribution, and Preliminary Evaluation of Clinical Activity in 5 Patients
    Kelley, Scott
    Kivitz, Alan
    Senter, Becca
    Golod, David
    Cinar, Amy
    Martin, Emily Walsh
    Hong, Won
    MOLECULAR THERAPY, 2021, 29 (04) : 288 - 288
  • [3] Safety and Preliminary Efficacy of PCRX201, an Intra-Articular Gene Therapy for Knee Osteoarthritis: A Phase 1, Open-Label, Single Ascending Dose Study
    Cohen, Stanley
    Kivitz, Alan
    Klassen, Lynell
    Nakazawa, Masato
    Parenti, Dennis
    DiGiorgi, Mary
    Winston, Roy
    MOLECULAR THERAPY, 2023, 31 (04) : 649 - 649
  • [4] Interim Safety, Efficacy and Achievement of Developmental Milestones in this Phase 1, First-In-Human Study of the Systemic Delivery of AVXS-101, an AAV9-Mediated Gene Therapy for Children with Spinal Muscular Atrophy (SMA) Type 1
    Sproule, D.
    Al-Zaidy, S.
    Shell, R.
    Arnold, D.
    Rodino-Klapac, L.
    Kissel, J.
    Prior, T.
    Miranda, C.
    Lowes, L.
    Alfano, L.
    Berry, K.
    Nagendran, S.
    Cardenas, J.
    Petek, C.
    Church, K.
    Burghes, A.
    Foust, K.
    Meyer, K.
    Likhite, S.
    Kaspar, B.
    Mendell, J.
    ANNALS OF NEUROLOGY, 2016, 80 : S367 - S367
  • [5] A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia
    Sivapalaratnam, Suthesh
    Austin, Steve
    Lorch, Ulrike
    York, Thomas
    Want, Andrew
    Gosnell, Ashley
    Gandhi, Prafull S.
    Ostergaard, Henrik
    Bjornson, Erik
    O'Meara, Tara
    Sorensen, Benny
    Schutgens, Roger E. G.
    Rea, Catherine
    BLOOD, 2023, 142
  • [6] XC001 gene therapy for the treatment of refractory angina: 6-month efficacy and safety from the phase 1/2 first-in-human study (EXACT Trial)
    Stewart, D. J.
    Dittrich, H. C.
    Reinhardt, R. R.
    Rosengart, T. K.
    Crystal, R. G.
    Povsic, T. J.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A44 - A44
  • [7] PRELIMINARY RESULTS FROM A PHASE 1B DOUBLE-BLIND STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF INTRA-ARTICULAR ADMINISTRATION OF RESINIFERATOXIN OR PLACEBO FOR THE TREATMENT OF MODERATE TO SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE
    Leiman, D.
    Minkowitz, H.
    Levitt, R. C.
    Solanki, D.
    Horn, D.
    Janfaza, D.
    Sarno, D.
    Albores-Ibarra, N.
    Bai, X.
    Takeshita, K.
    Zhao, T.
    Lu, C. -W.
    Bharathi, P.
    Ahern, J.
    Klincewicz, S.
    Nedeljkovic, S. S.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 : S138 - S138
  • [8] A first-in-human, phase 1, open-label trial of FX201, an intra-articular, helper-dependent adenoviral gene therapy for osteoarthritis - preliminary evaluation of clinical activity in 8 patients from the mid-dose cohort of a single ascending dose study design
    Kivitz, A.
    Senter, B.
    Golod, D.
    Parenti, D.
    Cinar, A.
    Hong, W.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A73 - A73
  • [9] Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
    Moore, Kathleen N.
    Sabanathan, Dhanusha
    Du, Yiqun
    Duan, Huaxin
    Li, Xiumin
    Wang, Feng
    Marathe, Omkar
    Yang, Hua
    Makker, Vicky
    Growdon, Whitfield
    Coward, Jim
    Zhao, Peng
    Liu, Liming
    Shi, Rong
    Liu, Shengxue
    Gu, Wei
    Qiu, Yang
    Zhu, Zhongyuan
    Zhang, Jian
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
    Yazici, Yusuf
    McAlindon, Timothy E.
    Fleischmann, Roy
    Gibofsky, Allan
    Lane, Nancy E.
    Kivitz, Alan J.
    Skrepnik, Nebojsa
    Armas, Eddie
    Swearingen, Christopher J.
    DiFrancesco, Anita
    Tambiah, Jeyanesh R. S.
    Hood, John
    Hochberg, Marc C.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345